Osteoconductive Scaffold Supports Bone Fusion

A new bone void filler provides a collagen matrix designed for use in spinal fusion and in reconstructive surgery of the extremities.

The Integra Mozaik osteoconductive scaffold is composed of highly purified beta-tricalcium phosphate and type-I collagen in a highly interconnected porous matrix. The scaffold can be used with bone marrow aspirate from the patient, sparing the need to harvest bone from the patient's iliac crest, and saving the patient additional surgery and postoperative pain. The scaffold is designed to imbibe and retain the aspirate and create an environment favorable for the binding, migration, and growth of cells.

The Mozaik osteoconductive scaffold is available in two forms: moldable putty, and a compression-resistant strip. Both the putty and strip can be tailored to size and provide the space-filling capacity that aids in controlling the location and volume of bone that is formed. The scaffold is intended for use in posterolateral lumbar fusion and in interbody fusion. The Mozaik is a product of Integra LifeSciences (Plainsboro, NJ, USA), and has been approved by the U.S. Food and Drug Administration (FDA).

"Integra Mozaik osteoconductive scaffold leverages Integra's expertise in regenerative technologies. Examples of other regenerative technologies include IntegraDermal Regeneration Template, the DuraGen family of products and NeuraGen Nerve Guide,” said Stuart Essig, president and CEO of Integra. "The introduction of Integra Mozaik Osteoconductive Scaffold reinforces our intention to build a business in spine and represents another milestone in Integra's history as a leader in regenerative technologies.”


Related Links:
Integra LifeSciences